Placentia, CA – June 30, 2025 — Applied Biomedicals is proud to announce the appointment of Mr. Dean Petkanas to its Executive Board, marking a significant step forward in the company’s commitment to advancing breakthrough biomedical technologies through strategic leadership and innovation-driven growth.

A highly respected corporate finance and executive management professional, Mr. Petkanas brings over 25 years of experience in investment banking, capital markets, and pharmaceutical commercialization to Applied Biomedicals. His deep expertise in biotechnology business development and regulatory strategy is expected to provide critical guidance as the company expands its footprint in clinical diagnostics, translational medicine, and global commercialization initiatives.

Mr. Petkanas is best known as the Co-Founder and former CEO of Kannalife Sciences, Inc., where he led the company’s foundational vision, licensing strategy, and capitalization. He was instrumental in securing the exclusive rights to U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants,” from the National Institutes of Health, aimed at addressing complex neurodegenerative conditions including Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE).

As a named co-inventor on two U.S. patents—#9611213 and #10004722—Mr. Petkanas has contributed significantly to the development of next-generation cannabidiol-derived therapeutics, including the neuroprotective compound KLS-13019, which has been highlighted in peer-reviewed publications such as ACS Medicinal Chemistry Letters and the Journal of Molecular Neuroscience.

“We are honored to welcome Dean Petkanas to the Executive Board,” said [Name], CEO of Applied Biomedicals. “Dean’s visionary leadership, proven track record in biotech financing, and ability to navigate complex regulatory pathways will be instrumental as we scale our platform and bring disruptive innovations to market.”

Mr. Petkanas’s pharmaceutical legacy also includes his tenure at Xechem International, Inc., where he served as Vice President of Business Development. He was directly involved in taking the company public, securing EXIM Bank financing, and playing a key leadership role in developing Hemoxin (Nicosan), a phyto-pharmaceutical compound for Sickle Cell Disease (SCD). He also led Xechem’s antitrust litigation efforts against Bristol-Myers Squibb regarding the cancer drug Taxol®, highlighting his commitment to equity in drug access and intellectual property fairness.

Mr. Petkanas’s appointment underscores Applied Biomedicals’ dedication to strategic growth, regulatory excellence, and the acceleration of high-impact diagnostics and therapeutics.